Cloud computing startup Modal Labs Inc. has raised $80 million in Series B funding and achieved “unicorn” status as it strives to become the infrastructure platform of choice for every stage of ...
HONG KONG—TAP Air Portugal CEO Luís Rodrigues says the carrier is entering a pivotal phase as the Portuguese government launches a partial privatization process, stressing that operational excellence ...
More recently, Lance Johnston, a recent college graduate, lost $4,000 in West Town. After leaving a doctor’s office, Johnston was approached by a group of men who said they were collecting money for a ...
Nestle SA has appointed Morgan Stanley for a strategic review of its vitamin business, according to people familiar with the matter, as the world’s largest food company looks to revive growth. The ...
The stages are set — three of them, in fact, across 11 consecutive hours of premium airtime with tens of millions of college football fans tuning in. Are the top programs on the West Coast ready for ...
Forbes contributors publish independent expert analyses and insights. Fred L. Smith Jr. Fellow at the Competitive Enterprise Institute. Early in the first Trump administration, agencies were directed ...
GRAND RAPIDS, MI — Members of the DeVos and Van Andel families have tapped a Chicago firm to lead their push to transform a riverfront parking lot in downtown Grand Rapids into a massive residential ...
Week 4 of the college football season featured some notable rivalry games, including a few in the Big Ten. The marquee game in the Big Ten featured two of the conference's ranked teams who have ...
Rutgers begins Big Ten play on Friday night, when it hosts Iowa at SHI Stadium in Piscataway. The Scarlet Knights (3-0) look to defeat the Hawkeyes (2-1) for the first time in their fifth meeting. A ...
The 2026 Big Ten men's basketball tournament is expanding to include all 18 teams in the conference, the league announced on Thursday. The move comes after only 15 of the league's 18 teams were ...
Pfizer, Arvinas lose interest in commercializing PROTAC inhibitor, leading to layoffs at the biotech
Having already stripped back their development plans for the estrogen receptor (ER) degrader vepdegestrant on the back of mixed data, Pfizer and Arvinas have now decided to wash their hands of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback